Clinical Trials

The Mayo Clinic Upper Digestive Disease Survey has been created in order to have a consistent evaluation tools for patients undergoing esophageal reconstruction or treatment  or patients that are experiencing an upper digestive disease in order to standardize and validate outcome measures.  Data will be used to establish the validation of the questionnaires/survey.  Data will also lead to the establishment of “normal” or expected scores for patients undergoing each type of esophagectomy procedure and for upper digestive diseases.  Data will contribute to creating treatment algorithms for symptom management for upper digestive diseases and for post-operative complications and symptoms as ...

The purpose of this study is to get definite evidence for the effectiveness of a short preoperative inspiratory muscle training protocol on the level of sickness and recovery of patients who are having the surgical removal of a portion of the esophagus.

The aim of this study is to assess quality of life in patients following esophageal resection for achalasia.

The purpose of this study is to learn about why esophageal cancer develops. We would like to test the tissue to find out which way of saving esophageal tissue gives us the best information (DNA and RNA) to use for future studies and collect a blood sample to use as a comparison for normal and tumor DNA.

The purpose of this study is to better understand how esophageal cells change with age.

The purpose of this study is to anayze the usefulness of treatment with nivolumab and ipilimumab in addition to standard of care chemotherapy and radiation therapy in patients with esophageal and gastroesophageal junction adenocarcinoma who are undergoing surgery. Immunotherapy with antibodies, such as nivolumab and ipilimumab, may remove the brake on the body's immune system and may interfere with the ability of tumor cells to grow and spread. Chemotherapy and radiation therapy may reduce the tumor size and the amount of normal tissue that needs to be removed during surgery. A combined treatment with nivolumab and ipilimumab, chemotherapy, and radiation therapy ...

The aims of this study are to compare the diagnostic accuracy of FEHI, a non-invasive, non-drug, spectral imaging technology to current standard of care, ICG fluorescein imaging, with regard to intraoperative tissue ischemia, to estimate the optimal threshold value for SpO2 in FEHI to achieve optimal correlation with ICG imaging, and to compare the time needed to complete FEHI compared to ICG. These will be compared in the final 70% of cases to avoid learning curve bias on the first cases.

The investigators believe that the lessons learned from studies regarding 30-day and 90-day readmission are primarily due to failure of early symptom recognition, and medical error. Through the aid of remote monitoring and early symptom detection, the hypothesis for the current proposal is that interventions can be recommended in an earlier, remote fashion that may result in earlier post-surgical discharge, prevent decompensation, and prevent increased readmissions that have been associated with decreased LOS in other surgical populations.